ACE and myocardial infarction: Angiotensin-converting enzyme inhibitors (ACEi) and angiotensin receptor blockers (ARB) are effective and recommended therapies following myocardial infarction with reduced left ventricular ejection fraction (LVEF), symptoms of heart failure, chronic kidney disease, hypertension, and/or diabetes.1–6 Indeed, the use of these drugs is a quality indicator for individuals with reduced LVEF.7 There is, however, little knowledge on the effectiveness of ACEi/ARBs in those with myocardial infarction with preserved LVEF (≥50%).8